Bradley Duffy

Array ( [id] => 12286267 [patent_doc_number] => 09932411 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2018-04-03 [patent_title] => Antibodies [patent_app_type] => utility [patent_app_number] => 15/037929 [patent_app_country] => US [patent_app_date] => 2014-11-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 13 [patent_figures_cnt] => 16 [patent_no_of_words] => 34260 [patent_no_of_claims] => 24 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 31 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15037929 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10273956 [patent_doc_number] => 20150158952 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-06-11 [patent_title] => 'CYSTEINE ENGINEERED ANTI-TENB2 ANTIBODIES AND ANTIBODY DRUG CONJUGATES' [patent_app_type] => utility [patent_app_number] => 14/552244 [patent_app_country] => US [patent_app_date] => 2014-11-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 22 [patent_figures_cnt] => 22 [patent_no_of_words] => 32214 [patent_no_of_claims] => 43 [patent_no_of_ind_claims] => 5 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14552244 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9916674 [patent_doc_number] => 20150071880 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-03-12 [patent_title] => 'TREATMENT OF EPITHELIAL LAYER LESIONS' [patent_app_type] => utility [patent_app_number] => 14/546363 [patent_app_country] => US [patent_app_date] => 2014-11-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 4983 [patent_no_of_claims] => 17 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14546363 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11075758 [patent_doc_number] => 20160272722 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-09-22 [patent_title] => 'ANTIBODY AGAINST GD2-O-ACETYLATED GANGLIOSIDE WITH PRO-APOPTOTIC ACTIVITY' [patent_app_type] => utility [patent_app_number] => 15/035979 [patent_app_country] => US [patent_app_date] => 2014-11-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 5 [patent_no_of_words] => 7977 [patent_no_of_claims] => 22 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15035979 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11074328 [patent_doc_number] => 20160271292 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-09-22 [patent_title] => 'FUNCTIONALIZED MICROGELS WITH FIBRIN BINDING ELEMENTS' [patent_app_type] => utility [patent_app_number] => 15/035831 [patent_app_country] => US [patent_app_date] => 2014-11-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 13 [patent_figures_cnt] => 13 [patent_no_of_words] => 10651 [patent_no_of_claims] => 21 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15035831 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10333275 [patent_doc_number] => 20150218278 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-08-06 [patent_title] => 'Fn14 Binding Proteins and Uses Thereof' [patent_app_type] => utility [patent_app_number] => 14/529890 [patent_app_country] => US [patent_app_date] => 2014-10-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 82 [patent_figures_cnt] => 82 [patent_no_of_words] => 65522 [patent_no_of_claims] => 8 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14529890 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10233228 [patent_doc_number] => 20150118222 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-04-30 [patent_title] => 'TREATMENT USING BRUTON\'S TYROSINE KINASE INHIBITORS AND IMMUNOTHERAPY' [patent_app_type] => utility [patent_app_number] => 14/523782 [patent_app_country] => US [patent_app_date] => 2014-10-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 72 [patent_figures_cnt] => 72 [patent_no_of_words] => 110720 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 6 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14523782 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10281677 [patent_doc_number] => 20150166674 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-06-18 [patent_title] => 'ANTIBODIES AND IMMUNOCONJUGATES AND USES THEREFOR' [patent_app_type] => utility [patent_app_number] => 14/517682 [patent_app_country] => US [patent_app_date] => 2014-10-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 45 [patent_figures_cnt] => 45 [patent_no_of_words] => 74410 [patent_no_of_claims] => 54 [patent_no_of_ind_claims] => 5 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14517682 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11067721 [patent_doc_number] => 20160264684 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-09-15 [patent_title] => 'GLYCAN-INTERACTING COMPOUNDS AND METHODS OF USE' [patent_app_type] => utility [patent_app_number] => 15/028360 [patent_app_country] => US [patent_app_date] => 2014-10-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 8 [patent_figures_cnt] => 8 [patent_no_of_words] => 56257 [patent_no_of_claims] => 22 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15028360 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10219872 [patent_doc_number] => 20150104865 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-04-16 [patent_title] => 'ENGINEERED HETERODIMERIC PROTEIN DOMAINS' [patent_app_type] => utility [patent_app_number] => 14/505653 [patent_app_country] => US [patent_app_date] => 2014-10-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 16 [patent_figures_cnt] => 16 [patent_no_of_words] => 16527 [patent_no_of_claims] => 8 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14505653 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10761983 [patent_doc_number] => 20160108136 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-04-21 [patent_title] => 'RECOMBINANT ANTIBODY COMPOSITION' [patent_app_type] => utility [patent_app_number] => 14/501146 [patent_app_country] => US [patent_app_date] => 2014-09-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 29 [patent_figures_cnt] => 29 [patent_no_of_words] => 49797 [patent_no_of_claims] => 9 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14501146 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10974237 [patent_doc_number] => 20140377272 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2014-12-25 [patent_title] => 'ANTI-HER3 ANTIBODIES AND USES THEREOF' [patent_app_type] => utility [patent_app_number] => 14/480192 [patent_app_country] => US [patent_app_date] => 2014-09-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 6 [patent_no_of_words] => 14111 [patent_no_of_claims] => 17 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14480192 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11536933 [patent_doc_number] => 09611331 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2017-04-04 [patent_title] => 'Anti-HER3 antibodies and uses thereof' [patent_app_type] => utility [patent_app_number] => 14/480198 [patent_app_country] => US [patent_app_date] => 2014-09-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 6 [patent_no_of_words] => 14173 [patent_no_of_claims] => 13 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 70 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14480198 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11011063 [patent_doc_number] => 20160208016 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-07-21 [patent_title] => 'Anti-ADAM12 antibodies for the treatment of cancer' [patent_app_type] => utility [patent_app_number] => 14/915182 [patent_app_country] => US [patent_app_date] => 2014-08-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 35 [patent_figures_cnt] => 35 [patent_no_of_words] => 23870 [patent_no_of_claims] => 68 [patent_no_of_ind_claims] => 43 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14915182 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12486885 [patent_doc_number] => 09993566 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2018-06-12 [patent_title] => SEZ6 modulators and methods of use [patent_app_type] => utility [patent_app_number] => 14/915563 [patent_app_country] => US [patent_app_date] => 2014-08-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 72 [patent_figures_cnt] => 62 [patent_no_of_words] => 68813 [patent_no_of_claims] => 41 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 45 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14915563 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10961562 [patent_doc_number] => 20140364592 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2014-12-11 [patent_title] => 'CYTOTOXIC IMMUNOGLOBULIN' [patent_app_type] => utility [patent_app_number] => 14/470425 [patent_app_country] => US [patent_app_date] => 2014-08-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 27 [patent_figures_cnt] => 27 [patent_no_of_words] => 32340 [patent_no_of_claims] => 21 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14470425 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9805226 [patent_doc_number] => 20150017168 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-01-15 [patent_title] => 'DUAL VARIABLE DOMAIN IMMUNOGLOBULINS AND USES THEREOF' [patent_app_type] => utility [patent_app_number] => 14/332087 [patent_app_country] => US [patent_app_date] => 2014-07-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 1 [patent_figures_cnt] => 1 [patent_no_of_words] => 84458 [patent_no_of_claims] => 33 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14332087 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13944709 [patent_doc_number] => 10208110 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-02-19 [patent_title] => Compositions and methods related to recombinant antibodies to histone posttranslational modifications [patent_app_type] => utility [patent_app_number] => 14/900692 [patent_app_country] => US [patent_app_date] => 2014-06-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 45 [patent_figures_cnt] => 60 [patent_no_of_words] => 38447 [patent_no_of_claims] => 1 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 54 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14900692 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13636809 [patent_doc_number] => 09845361 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2017-12-19 [patent_title] => Recognition molecules for the treatment and detection of tumors [patent_app_type] => utility [patent_app_number] => 14/316389 [patent_app_country] => US [patent_app_date] => 2014-06-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 21 [patent_figures_cnt] => 21 [patent_no_of_words] => 22490 [patent_no_of_claims] => 7 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 222 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14316389 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11794122 [patent_doc_number] => 09403872 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2016-08-02 [patent_title] => 'Mutated anthrax toxin protective antigen proteins that specifically target cells containing high amounts of cell-surface metalloproteinases or plasminogen activator receptors' [patent_app_type] => utility [patent_app_number] => 14/313575 [patent_app_country] => US [patent_app_date] => 2014-06-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 18 [patent_figures_cnt] => 17 [patent_no_of_words] => 23456 [patent_no_of_claims] => 5 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 76 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14313575 [rel_patent_id] =>[rel_patent_doc_number] =>)